A TTO's Guide to Patent Commercialization Metrics

The metrics technology transfer offices actually track — disclosures, filings, licenses, startups, and revenue — including the AUTM survey framework and which numbers signal real commercialization health.

If you cannot measure commercialization, you cannot improve it. But tech transfer metrics are easy to misread — a single blockbuster deal can flatter a mediocre year, and a strong pipeline can look weak if you only watch revenue. Here is the metric set that actually describes the health of a technology transfer operation.

The standard framework: AUTM

Most U.S. and Canadian institutions benchmark against the AUTM Licensing Activity Survey, run annually by the Association of University Technology Managers. It collects standardized figures across institutions, which is why its categories have become the common vocabulary of the field. The core metrics it tracks are a good starting point for any office.

Input and activity metrics

• Invention disclosures — the top of the funnel. Trends here reflect research output and how well the office engages faculty.
• Patent applications filed — how much of the pipeline you are choosing to protect.
• Patents issued — a lagging indicator, given multi-year prosecution timelines.

Outcome metrics

• Licenses and options executed — the clearest sign that technology is moving to market. Watch the count, not just the dollar value.
• Startups formed — companies launched around institutional IP, a key economic-impact measure (and the subject of our spinout vs. license guide).
• Licensing revenue — real, but skewed. A handful of deals can dominate, so read it alongside the others.

The metrics that predict the future

Lagging metrics like revenue tell you about last decade's research. Leading indicators tell you where you are heading:

• Disclosure-to-deal conversion — what share of disclosures reach a license or startup.
• Time-to-license — how long technologies sit before finding a home.
• Active marketing coverage — what share of your licensable portfolio is actually being marketed, not just sitting on a webpage.
• Pipeline health — number of active licensee conversations underway.

The trap: vanity metrics

Patents filed and patents issued feel like progress, but a patent is a cost until it is licensed. An office optimizing for filings can quietly grow a large, expensive, unlicensed portfolio. Balance input metrics with outcome metrics, every quarter.

Benchmark against yourself first

AUTM lets you compare to peers, but institutions differ enormously in research mix, size, and field. The most actionable comparison is your own trend line over time. Pick a small set of leading and lagging metrics, report them consistently, and let the trend — not a single year — guide strategy.